Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
Authors' conclusion
In real-world use, tirzepatide significantly reduced HbA1c levels and weight and was well tolerated. Previous GLP-RA use was associated with significantly lesser HbA1c and weight reduction, and previous metabolic bariatric surgery was associated with greater weight loss.
Study context
- Population
- Arab patients with T2D initiating tirzepatide at a specialist outpatient diabetes centre (24 October 2022–31 December 2023); mean age 54.1 years, BMI 34.6 kg/m², HbA1c 7.3%3,686 reached 40 weeks
- Participants
- 8,945 patients
- Outcome
- Change in HbA1c and weight
- Follow-up
- 40 weeks
Methodological detailsreal-world, single-centre, pre-specified time points and outcome measures
- Real-world
- Single-centre
- Pre-specified time points and outcome measures
Main finding
As reported in the abstract
Mean reduction in HbA1c
0.6 ± 1.2%
8 ± 13 mmol/mol
Reduction in weight
4.5 ± 6.9 kg
4.8 ± 7.3%
Observational data: associations, not effects.
Further findings
HbA1c reduction by previous GLP-RA exposure · 40 weeks · greater reduction with GLP-RA-naïve
P < 0.0001
Weight reduction by previous GLP-RA exposure · 40 weeks · greater reduction with GLP-RA-naïve
P < 0.0001
Weight loss after previous metabolic bariatric surgery · 40 weeks
- Post-metabolic bariatric surgery patients lost significantly more weight; p < .0001
- 7.8 ± 9.4 vs. 4.5 ± 7.0 kg
Blood pressure, lipid profile and liver transaminases · 40 weeks
- Improvements in blood pressure, lipid profile and liver transaminases
Safety
Discontinuation due to adverse effects
- Discontinued because of adverse effects, predominantly gastrointestinal
- 288 (7.8%)
- Well tolerated
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →